NervGen Pharma Corp. (NGEN) stock
NGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.96+0.14 (+7.69%)
Close on Nov 17, 2026Market cap $156.11MP/E –Yield –
NervGen Pharma r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was C$13.47M, down 13.2% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | C$13.47M | -13.2% |
| FY2024 | Dec 31, 2024 | C$15.51M | – |
See a number that looks wrong?